219 related articles for article (PubMed ID: 20456344)
1. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
Downs AM
Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
[No Abstract] [Full Text] [Related]
2. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
3. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
4. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
5. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
6. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
Sánchez-Moya AI; Daudén E
Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
[No Abstract] [Full Text] [Related]
8. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
9. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of biologics with traditional agents in psoriasis.
Guenther LC
Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
[TBL] [Abstract][Full Text] [Related]
11. Switching biologics for psoriasis.
Ormerod AD
Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
[No Abstract] [Full Text] [Related]
12. Infliximab: efficacy in psoriasis.
Arsiwala S
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
[TBL] [Abstract][Full Text] [Related]
13. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
14. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
15. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
De Angelis R; Gasparini S; Bugatti L; Filosa G
Dermatology; 2005; 210(3):241-3. PubMed ID: 15785057
[No Abstract] [Full Text] [Related]
16. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
Moreno-Ramírez D
Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
[No Abstract] [Full Text] [Related]
17. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
18. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
19. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure.
Golberg O; Osborne JE; Hutchinson PE
Br J Dermatol; 2011 Feb; 164(2):459-60. PubMed ID: 20973773
[No Abstract] [Full Text] [Related]
20. Hair regrowth following TNF-α blockade in coexisting psoriasis vulgaris and alopecia areata.
Ono S; Miyachi Y; Arakawa A
Eur J Dermatol; 2013; 23(4):537. PubMed ID: 24047580
[No Abstract] [Full Text] [Related]
[Next] [New Search]
